[Innovations in peritoneal dialysis].

Q4 Medicine Nephrologe Pub Date : 2022-01-01 Epub Date: 2021-11-12 DOI:10.1007/s11560-021-00542-x
R Hausinger, C Schmaderer, U Heemann, Q Bachmann
{"title":"[Innovations in peritoneal dialysis].","authors":"R Hausinger,&nbsp;C Schmaderer,&nbsp;U Heemann,&nbsp;Q Bachmann","doi":"10.1007/s11560-021-00542-x","DOIUrl":null,"url":null,"abstract":"<p><p>Peritoneal dialysis used to be a common treatment for acute kidney failure that required dialysis. In favor of continuous, extracorporeal renal replacement procedures, it disappeared from the scene in the western world, whereas it continues to be used in structurally poor countries due to its simplicity and low resource intensity. Recently, the shortages in medical care in the context of the coronavirus disease 2019 (COVID-19) pandemic led to renewed worldwide interest in peritoneal dialysis as a safe option in acute kidney failure requiring dialysis. The introduction of biocompatible solutions 20 years ago was expected to reduce mortality or technical failure. Unfortunately, so far this could only be implied but not confirmed in studies. Immunomodulatory adjuvants are an innovative option which have the potential to improve the local immunocompetence and prevent the loss of peritoneal function. Currently, the vision of a wearable artificial kidney is getting closer. Intensification of dialysis dose also appears achievable with minimal dialysate volumes. In times of global warming, the regeneration of dialysates could not only save relevant amounts of water but also have a favorable impact on the CO<sub>2</sub> balance. In summary, peritoneal dialysis is currently enjoying a comeback. This article describes the current and future developments of this procedure.</p>","PeriodicalId":41844,"journal":{"name":"Nephrologe","volume":"17 2","pages":"85-91"},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8588934/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nephrologe","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s11560-021-00542-x","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/11/12 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Peritoneal dialysis used to be a common treatment for acute kidney failure that required dialysis. In favor of continuous, extracorporeal renal replacement procedures, it disappeared from the scene in the western world, whereas it continues to be used in structurally poor countries due to its simplicity and low resource intensity. Recently, the shortages in medical care in the context of the coronavirus disease 2019 (COVID-19) pandemic led to renewed worldwide interest in peritoneal dialysis as a safe option in acute kidney failure requiring dialysis. The introduction of biocompatible solutions 20 years ago was expected to reduce mortality or technical failure. Unfortunately, so far this could only be implied but not confirmed in studies. Immunomodulatory adjuvants are an innovative option which have the potential to improve the local immunocompetence and prevent the loss of peritoneal function. Currently, the vision of a wearable artificial kidney is getting closer. Intensification of dialysis dose also appears achievable with minimal dialysate volumes. In times of global warming, the regeneration of dialysates could not only save relevant amounts of water but also have a favorable impact on the CO2 balance. In summary, peritoneal dialysis is currently enjoying a comeback. This article describes the current and future developments of this procedure.

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
[腹膜透析的创新]。
腹膜透析曾经是需要透析的急性肾衰竭的常用治疗方法。为了支持持续的体外肾脏替代手术,它在西方世界消失了,而由于它的简单性和低资源强度,它在结构落后的国家继续使用。最近,在2019冠状病毒病(COVID-19)大流行的背景下,医疗保健短缺导致全世界重新关注腹膜透析作为需要透析的急性肾衰竭的安全选择。20年前,生物相容性解决方案的引入有望降低死亡率或技术故障。不幸的是,到目前为止,这只能是暗示,而没有得到研究的证实。免疫调节佐剂是一种创新的选择,具有提高局部免疫能力和防止腹膜功能丧失的潜力。目前,可穿戴人工肾脏的愿景越来越近。在透析液体积最小的情况下,强化透析剂量似乎也是可以实现的。在全球变暖的情况下,透析液的再生不仅可以节约相应的水量,而且对CO2平衡也有有利的影响。总之,腹膜透析目前正在恢复。本文描述了该程序的当前和未来发展。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Nephrologe
Nephrologe UROLOGY & NEPHROLOGY-
CiteScore
0.40
自引率
0.00%
发文量
25
期刊介绍: Zielsetzung der Zeitschrift Der Nephrologe bietet aktuelle und kompakte Fortbildung für alle nephrologisch tätigen Ärzt*innen in Klinik und Praxis. Inhaltlich werden sämtliche Bereiche der angewandten Nephrologie und Hypertensiologie praxisnah abgedeckt. Das Spektrum reicht von der Prävention, diagnostischen Vorgehensweisen und Komplikationsmanagement bis hin zu modernen Therapiestrategien. Umfassende Übersichtsarbeiten zu einem aktuellen Schwerpunktthema sind das Kernstück jeder Ausgabe. Im Mittelpunkt steht dabei gesichertes Wissen zu Diagnostik und Therapie mit hoher Relevanz für die tägliche Arbeit. Beiträge der Rubrik "CME Zertifizierte Fortbildung" bieten gesicherte Ergebnisse wissenschaftlicher Forschung und machen ärztliche Erfahrung für die tägliche Praxis nutzbar. Nach Lektüre der Beiträge können die Leser*innen ihr erworbenes Wissen überprüfen und online CME-Punkte erwerben. Die Rubrik orientiert sich an der Weiterbildungsordnung des Fachgebiets. Aims & Scope Der Nephrologe offers up-to-date information for all nephrologists working in practical and clinical environments and scientists who are particularly interested in issues of nephrology. The content covers all areas of applied nephrology and hypertensiology. The topics range from prevention to diagnostic approaches and management of complications to current therapy strategies. Comprehensive reviews on a specific topical issue provide evidenced based information on diagnostics and therapy. Review articles under the rubric ''Continuing Medical Education'' present verified results of scientific research and their integration into daily practice. Review All articles of Der Nephrologe are reviewed. Declaration of Helsinki All manuscripts submitted for publication presenting results from studies on probands or patients must comply with the Declaration of Helsinki.
期刊最新文献
Mitteilungen des BDI Treatment of idiopathic overactive bladder with botulinum toxin: real-life results and patients' expectations. Mitteilungen des BDI Kindernephrologie Erratum zu: Studientagung der Gesellschaft für Pädiatrische Nephrologie – Grundlage innovativer Forschung
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1